Boston Scientific Sustainability Profile
Boston Scientific Corporation, a leading global medical technology company, is headquartered in the United States. Founded in 1979, the company has established itself as a key player in the medical device industry, focusing on innovative solutions across various therapeutic areas, including cardiovascular, rhythm management, and urology. With a strong presence in North America, Europe, and Asia-Pacific, Boston Scientific is renowned for its advanced products and services, such as minimally invasive devices and cutting-edge imaging technologies. The company’s commitment to innovation is exemplified by its numerous milestones, including the development of the first drug-eluting stent. Recognised for its market leadership, Boston Scientific continues to push the boundaries of medical technology, enhancing patient outcomes and improving quality of life. Its dedication to research and development positions it as a trusted partner in healthcare worldwide.
DitchCarbon Score
How does Boston Scientific's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boston Scientific's score of 98 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boston Scientific's reported carbon emissions
In 2024, Boston Scientific reported total carbon emissions of approximately 1,675,000,000 kg CO2e, with significant contributions from Scope 1, 2, and 3 emissions. Specifically, Scope 1 emissions were about 87,567,000 kg CO2e, while Scope 2 emissions totalled approximately 9,854,000 kg CO2e. The majority of emissions stemmed from Scope 3, which accounted for about 1,663,859,000 kg CO2e, highlighting the extensive impact of their supply chain and product use. Boston Scientific has set ambitious climate commitments, aiming for carbon neutrality in all manufacturing and key distribution sites by 2030. This pledge is part of their broader strategy to achieve net-zero greenhouse gas emissions across the value chain by 2050, with interim targets of a 46.2% reduction in absolute Scope 1 and 2 emissions by 2030 from a 2019 baseline. Additionally, they aim to reduce Scope 3 emissions by 55% per USD value added within the same timeframe. The company has achieved a notable 68% reduction in greenhouse gas emissions since 2009 for Scope 1 and 2 combined. Their long-term goals include a 97% reduction in emissions per USD value added for both Scope 1 and 2 by 2050, which translates to a 90% absolute reduction. Boston Scientific's climate strategy is aligned with the Science Based Targets initiative (SBTi), ensuring that their targets are consistent with the global effort to limit warming to 1.5°C. This commitment reflects their dedication to sustainability and reducing their environmental impact in the healthcare equipment and supplies sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Boston Scientific's Industry?
How Carbon Intensive is Boston Scientific's Location?
Boston Scientific's Scope 3 Categories Breakdown
Boston Scientific's Scope 3 emissions, which increased by 28% last year and decreased by approximately 7% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 57% of Scope 3 emissions.
Top Scope 3 Categories
Boston Scientific's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Boston Scientific has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
St. Jude Medical, Inc.
Coloplast
Shandong Weigao Group Medical Polymer Company Limited
C. R. Bard, Inc.
Frequently Asked Questions
Common questions about Boston Scientific's sustainability data and climate commitments